Optimized lipid nanoparticles (LNPs) for organ-selective nucleic acids delivery in vivo DOI Creative Commons
Tian Zhang,

Han Yin,

Li Yu

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(6), P. 109804 - 109804

Published: April 23, 2024

Nucleic acid therapeutics offer tremendous promise for addressing a wide range of common public health conditions. However, the

Language: Английский

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy DOI
Yan Zong, Yi Lin, Tuo Wei

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 35(51)

Published: May 17, 2023

Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to success coronavirus disease 2019 (COVID‐19) mRNA vaccines (Comirnaty Spikevax). To meet therapeutic purpose, it is required that must enter target cells express sufficient proteins. Therefore, development effective delivery systems necessary crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle indeed accelerated applications humans, as several mRNA‐based therapies have already been approved or are clinical trials. In this review, focus on mRNA‐LNP‐mediated anticancer therapy. It summarizes main strategies mRNA‐LNP formulations, discusses representative approaches cancer, points out current challenges possible future directions research field. hoped these delivered messages can help further improve application technology cancer

Language: Английский

Citations

187

Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications DOI
Michaela Jeong, Yeji Lee, Jeongeun Park

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 200, P. 114990 - 114990

Published: July 7, 2023

Language: Английский

Citations

95

The 60-year evolution of lipid nanoparticles for nucleic acid delivery DOI
Pieter R. Cullis, Philip L. Felgner

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: 23(9), P. 709 - 722

Published: July 4, 2024

Language: Английский

Citations

78

Lipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid DOI

Yaru Jia,

Xiu‐Guang Wang,

Luwei Li

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(4)

Published: Aug. 7, 2023

Abstract Lipid nanoparticles (LNPs) are currently the most promising clinical nucleic acids drug delivery vehicles. LNPs prevent degradation of cargo during blood circulation. Upon entry into cell, specific components lipid can promote endosomal escape acids. These basic properties as acid carriers. As exhibit hepatic aggregation characteristics, enhancing targeting out liver is a crucial way to improve administrated in vivo. Meanwhile, loaded often considered inadequate, and therefore, much effort devoted intracellular release efficiency Here, different strategies efficiently deliver from concluded their mechanisms investigated. In addition, based on information that trials or have completed trials, issues necessary be approached translation discussed, which it hoped will shed light development LNP drugs.

Language: Английский

Citations

59

Strategies for non-viral vectors targeting organs beyond the liver DOI
Jeonghwan Kim, Yulia Eygeris, Renee C. Ryals

et al.

Nature Nanotechnology, Journal Year: 2023, Volume and Issue: 19(4), P. 428 - 447

Published: Dec. 27, 2023

Language: Английский

Citations

59

Engineering nanoparticle toolkits for mRNA delivery DOI Creative Commons
Bing Sun,

Weixi Wu,

Eshan A. Narasipura

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 200, P. 115042 - 115042

Published: Aug. 2, 2023

The concept of using mRNA to produce its own medicine in situ the body makes it an ideal drug candidate, holding great potential revolutionize way we approach medicine. unique characteristics mRNA, as well customizable biomedical functions, call for rational design delivery systems protect and transport molecules. In this review, a nanoparticle toolkit is presented development mRNA-based therapeutics from perspective. Nano-delivery derived either natural or chemical synthesis, nature organic inorganic materials, are summarised. Delivery strategies controlling tissue targeting release, role nanoparticles building boosting activity drugs, have also been introduced. end, our insights into clinical translational nano-drugs presented.

Language: Английский

Citations

54

Physiological Barriers and Strategies of Lipid‐Based Nanoparticles for Nucleic Acid Drug Delivery DOI
Mingdi Hu, Xiaoyan Li, Zhen You

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 4, 2023

Abstract Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic acid drug (NAD) delivery. Although their clinical applications have achieved success, NAD delivery efficiency and safety still unsatisfactory, which are, to a large extent, due existence of multi‐level physiological barriers in vivo. It is important elucidate interactions between these LBNPs, will guide more rational design efficient with low adverse effects facilitate broader therapeutics. This review describes obstacles challenges biological at systemic, organ, sub‐organ, cellular, subcellular levels. The strategies overcome comprehensively reviewed, mainly including physically/chemically engineering LBNPs directly modifying by auxiliary treatments. Then potentials successful translation preclinical studies into clinic discussed. In end, forward look on manipulating protein corona (PC) addressed, may pull off trick overcoming those significantly improve efficacy LBNP‐based NADs

Language: Английский

Citations

53

Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina DOI Creative Commons
Milan Gautam, Antony Jozić, Grace Su

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Oct. 13, 2023

Abstract Ocular delivery of lipid nanoparticle (LNPs) packaged mRNA can enable efficient gene and editing. We generated LNP variants through the inclusion positively charged-amine-modified polyethylene glycol (PEG)-lipids (LNPa), negatively charged-carboxyl-(LNPz) carboxy-ester (LNPx) modified PEG-lipids, neutral unmodified PEG-lipids (LNP). Subretinal injections LNPa containing Cre in mouse show tdTomato signal retinal pigmented epithelium (RPE) like conventional LNPs. Unexpectedly, LNPx LNPz 27% 16% photoreceptor transfection, respectively, with striking localization extending from synaptic pedicle to outer segments, displaying pan-retinal distribution photoreceptors RPE. Cas9 sgAi9 leads formation an oval elongated structure a charge resulting 16.4% editing restricted Surface modifications LNPs PEG alter cellular tropism mRNA. genome retina future be used correct genetic mutations that lead blindness.

Language: Английский

Citations

49

Recent advances in nanoparticulate RNA delivery systems DOI Creative Commons
Jacob Witten, Yizong Hu, Róbert Langer

et al.

Proceedings of the National Academy of Sciences, Journal Year: 2024, Volume and Issue: 121(11)

Published: March 4, 2024

Nanoparticle-based RNA delivery has shown great progress in recent years with the approval of two mRNA vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a liver-targeted siRNA therapy. Here, we discuss preclinical clinical advancement new generations therapies along multiple axes. Improvements cargo design such as circularization data-driven untranslated region optimization can drive better expression. New materials discovery research driven improved to extrahepatic targets lung splenic immune cells, which could lead pulmonary gene therapy cancer vaccines, respectively. Other organs even specific cell types be targeted via conjugation small molecule ligands, antibodies, or peptides nanoparticles. Moreover, response any nanoparticle plays crucial role determining efficacy. Targeting increased immunogenicity without induction reactogenic side effects is while minimization important therapies. developments have addressed each these priorities. Last, range trials targeting diverse organs, types, diseases suggest some key advances that may play next wave

Language: Английский

Citations

36

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases DOI Creative Commons
Yue Wu, Xin Li,

Xueyu Fu

et al.

Advanced Science, Journal Year: 2024, Volume and Issue: 11(32)

Published: June 21, 2024

Abstract Funduscopic diseases, including diabetic retinopathy (DR) and age‐related macular degeneration (AMD), significantly impact global visual health, leading to impaired vision irreversible blindness. Delivering drugs the posterior segment of eye remains a challenge due presence multiple physiological anatomical barriers. Conventional drug delivery methods often prove ineffective may cause side effects. Nanomaterials, characterized by their small size, large surface area, tunable properties, biocompatibility, enhance permeability, stability, targeting drugs. Ocular nanomaterials encompass wide range, lipid nanomaterials, polymer metal carbon quantum dot so on. These innovative materials, combined with hydrogels exosomes, are engineered address mechanisms, macrophage polarization, reactive oxygen species (ROS) scavenging, anti‐vascular endothelial growth factor (VEGF). Compared conventional modalities, nanomedicines achieve regulated sustained delivery, reduced administration frequency, prolonged action, minimized This study delves into obstacles encountered in highlights progress facilitated nanomedicine. Prospectively, these findings pave way for next‐generation ocular systems deeper clinical research, aiming refine treatments, alleviate burden on patients, ultimately improve health globally.

Language: Английский

Citations

26